Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia

Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia
复制标题

DOI:
10.1016/j.bbmt.2019.10.004
复制
发表时间:
2020-03-01
影响因子:
4.3
通讯作者:
Mori, Takehiko
Mori, Takehiko
中科院分区:
医学2区
文献类型:
--
作者:
Kako, Shinichi;Yamazaki, Hirohito;Mori, Takehiko

文献摘要

被引文献

相似文献

混合嵌合体(MC)和/或继发性移植物衰竭(SGF)与受体或供体型嵌合体是异基因移植治疗再生障碍性贫血(AA)的主要障碍。根据日本的登记数据库,本研究纳入了年龄>15岁、在2000年至2014年期间接受首次异基因骨髓或外周血干细胞移植并实现植入的AA患者。不需要粒细胞集落刺激因子(G-CSF)或输血支持的MC(第1组),需要G-CSF和/或输血支持的MC(非SGF)(第2组),具有MC或完全免疫型嵌合体的SGF(第3组)和具有完全供体型嵌合体的SGF(第4组)分别在26、16、19和17例患者中发生。幸存者的总体中位随访时间为1727天。无MC或SGF患者(n = 340)的1年总生存率(OS)为90.4%,5年为83.5%,与第1组和第2组的OS无差异。然而,第3组(1年,52.1%; 5年,52.1%)和第4组(1年,82.4%; 5年,56.3%)的OS较差。在多变量分析中,使用氟达拉滨(Flu)和在条件反射中不照射与SGF伴MC或完全免疫型嵌合体的发展相关,而在条件反射中使用Flu与SGF伴完全供体型嵌合体相关。总之,流感的使用可能会影响SGF的发生与免疫型和供体型嵌合体。(C)2019年美国移植和细胞治疗学会。爱思唯尔公司出版
Mixed chimerism (MC) and/or secondary graft failure (SGF) with recipient- or donor-type chimerism is a major obstacle in allogeneic transplantation for aplastic anemia (AA). From a registry database in Japan, patients with AA age >15 years who underwent a first allogeneic bone marrow or peripheral blood stem cell transplantation between 2000 and 2014 and achieved engraftment were included in this study. MC that did not require either granulocyte-colony stimulating factor (G-CSF) or transfusion support (group 1), MC (not SGF) that required G-CSF and/or transfusion support (group 2), SGF with MC or complete recipient-type chimerism (group 3), and SGF with complete donor-type chimerism (group 4) developed in 26, 16, 19, and 17 patients, respectively. The overall median duration of follow-up for survivors was 1727 days. The overall survival (OS) was 90.4% at 1 year and 83.5% at 5 years in patients without MC or SGF (n = 340), which was not different from the OS in groups 1 and 2. However, inferior OS was observed in group 3 (1 year, 52.1%; 5 years, 52.1%) and group 4 (1 year, 82.4%; 5 years, 56.3%). In multivariate analyses, the use of fludarabine (Flu) and the absence of irradiation in conditioning were associated with the development of SGF with MC or complete recipient-type chimerism, and the use of Flu in conditioning was associated with SGF with complete donor-type chimerism. In conclusion, the use of Flu may affect the occurrence of SGF with both recipient-type and donor-type chimerism. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.